Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation

被引:21
|
作者
Matsuo, K
Hamajima, N
Morishima, Y
Harada, M
机构
[1] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Chikusa Ku, Nagoya, Aichi 464, Japan
[2] Nagoya Univ, Grad Sch Med, Nagoya, Aichi, Japan
[3] Japan Soc Hematopoiet Cell Transplantat, Off Nationwide Survey, Nagoya, Aichi, Japan
[4] Aichi Canc Ctr Hosp, Dept Hematol & Chemotherapy, Nagoya, Aichi 464, Japan
[5] Okayama Univ, Sch Med, Dept Internal Med 2, Okayama 700, Japan
关键词
hospital mortality; bone marrow transplantation; allogeneic transplantation; survival analysis;
D O I
10.1038/sj.bmt.1702681
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The association between hospital capacity and survival after allogeneic bone marrow transplantation (allo-BMT) was examined using the dataset accumulated by the Japan Society of Hematopoietic Cell Transplantations (JSHCT). The subjects were 3134 patients who received first allo-BMTs between 1991 and 1997 reported to the JSHCT, They were divided into three groups by cumulative hospital experience of allo-BMTs: low volume (capacity) (LV; less than or equal to 25 cases), moderate volume (capacity) (MV; 26-75 cases) and high volume (capacity) (HV; greater than or equal to 76 cases). Using a proportional hazards model, the association of hospital experience with early survival at day 100 (D100S), and overall survival (OS) were examined. For leukemia patients, leukemia-free survival (LFS) was also analyzed. When HV was defined as the reference group, the hazard ratios (HRs) of OS for all subjects were 1.10 (95% confidence interval; 0.97-1.25) for MV and 1.25 for LV (1.08-1.44), The HRs with D100S were 1.20 (0.96-1.51) for MV and 1.40 (1.08-1.80) for LV, Larger values were observed for OS and D100S in cases of leukemia. Survival after BMT from sibling donors was clearly influenced by hospital experience, but this was not the case from unrelated donors. These findings suggest that size of the transplant team should be considered in order to improve the outcome of sibling BMT in general.
引用
收藏
页码:1061 / 1067
页数:7
相关论文
共 50 条
  • [1] Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation
    K Matsuo
    N Hamajima
    Y Morishima
    M Harada
    Bone Marrow Transplantation, 2000, 26 : 1061 - 1067
  • [2] Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide
    Hebert, Courtney
    Watts, Nicole
    Isaac, Shiney
    Kukkamalla, Rivvi
    Jamy, Omer
    Saad, Ayman
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S276 - S277
  • [3] Hyponatremia induced by post-transplant cyclophosphamide in allogeneic hematopoietic cell transplantation
    Gomez-Hernando, Marta
    Quintana, Luis F.
    Suarez-Lledo, Maria
    Martinez-Cibrian, Nuria
    Rivero, Andrea
    Ruiz-Boy, Sonia
    Carcelero, Ester
    Mate, Paula
    Riu, Gisela
    Monge, Ines
    Serrahima, Anna
    Solano, Maria Teresa
    Rosinol, Laura
    Esteve, Jordi
    Urbano-Ispizua, Alvaro
    Carreras, Enric
    Fernandez-Aviles, Francesc
    Martinez, Carmen
    Rovira, Montserrat
    Salas, Maria Queralt
    BONE MARROW TRANSPLANTATION, 2023, 58 (02) : 212 - 214
  • [4] Hyponatremia induced by post-transplant cyclophosphamide in allogeneic hematopoietic cell transplantation
    Marta Gómez-Hernando
    Luis F. Quintana
    María Suárez-Lledo
    Nuria Martínez-Cibrian
    Andrea Rivero
    Sonia Ruiz-Boy
    Ester Carcelero
    Paula Mate
    Gisela Riu
    Inés Monge
    Anna Serrahima
    Maria Teresa Solano
    Laura Rosiñol
    Jordi Esteve
    Alvaro Urbano-Ispizua
    Enric Carreras
    Francesc Fernández-Avilés
    Carmen Martínez
    Montserrat Rovira
    Maria Queralt Salas
    Bone Marrow Transplantation, 2023, 58 : 212 - 214
  • [5] Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?
    Mohty, Razan
    Al Kadhimi, Zaid
    Kharfan-Dabaja, Mohamed
    HEMATOLOGY, 2024, 29 (01)
  • [6] Extracellular Vesicles After Allogeneic Hematopoietic Cell Transplantation: Emerging Role in Post-Transplant Complications
    Lia, Giuseppe
    Di Vito, Clara
    Cerrano, Marco
    Brunello, Lucia
    Calcaterra, Francesca
    Tapparo, Marta
    Giaccone, Luisa
    Mavilio, Domenico
    Bruno, Benedetto
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [7] OVERVIEW OF POST-TRANSPLANT MONITORING IN PATIENTS AFTER HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Cechova, Hana
    Pegova, Kristyna
    Pavlatova, Lucie
    Zizkova, Radka
    Hrabakova, Pavla
    Prerovska, Renata
    Stankova, Martina
    Brezinova, Dagmar
    HLA, 2018, 91 (05) : 403 - 404
  • [8] Burden of Post-Transplant Lymphoproliferative Disorder-Mortality After Allogeneic Hematopoietic Cell Transplantation
    Katz, Aaron
    Barlev, Arie
    Joshi, A. J.
    BONE MARROW TRANSPLANTATION, 2018, 53 : 305 - 306
  • [9] ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELOFIBROSIS - CLOSE POST-TRANSPLANT SURVEILLANCE IS MANDATORY
    Baurmann, H.
    Thiede, C.
    Burlakova, I
    Judith, D.
    Heshmat, M.
    Schleuning, M.
    Schwerdtfeger, R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S289 - S289
  • [10] Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation
    Masatoshi Sakurai
    Takehiko Mori
    Koji Kato
    Minoru Kanaya
    Shohei Mizuno
    Souichi Shiratori
    Toshio Wakayama
    Naoyuki Uchida
    Hikaru Kobayashi
    Kohmei Kubo
    Itsuto Amano
    Takanori Ohta
    Yasuhiko Miyazaki
    Junya Kanda
    Takahiro Fukuda
    Yoshiko Atsuta
    Eisei Kondo
    Bone Marrow Transplantation, 2021, 56 : 1462 - 1466